{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:42:20Z","timestamp":1790109740584,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008244.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000}}],"reference-count":78,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008244.pub3","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T14:50:36Z","timestamp":1445352636000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Milnacipran for pain in fibromyalgia in adults"],"prefix":"10.1002","volume":"2019","author":[{"given":"Malene","family":"Cording","sequence":"first","affiliation":[{"name":"University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[{"name":"Oxford Oxfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of Oxford; Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics); Churchill Hospital Oxford UK OX3 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Wiffen","sequence":"additional","affiliation":[{"name":"Thame UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD008244.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/art.27559","article-title":"Efficacy and safety of milnacipran 100mg\/day in patients with fibromyalgia","volume":"62","author":"Arnold","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008244.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.psym.2012.02.005","article-title":"Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran","volume":"53","author":"Arnold","year":"2012","journal-title":"Psychosomatics"},{"issue":"5","key":"10.1002\/14651858.CD008244.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1185\/03007995.2012.677418","article-title":"Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia","volume":"28","author":"Saxe","year":"2012","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0005|cit4","unstructured":"Study of milnacipran in patients with inadequate response to duloxetine for the treatment of fibromyalgia, 2011 www.clinicaltrials.gov\/ct2\/show\/study\/NCT01077375"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0004|cit5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/JPR.S43395","article-title":"Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study","volume":"6","author":"Bateman","year":"2013","journal-title":"Journal of Pain Research"},{"issue":"7","key":"10.1002\/14651858.CD008244.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3899\/jrheum.101025","article-title":"Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study","volume":"38","author":"Branco","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008244.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3899\/jrheum.090884","article-title":"A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia","volume":"37","author":"Branco","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD008244.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","article-title":"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial","volume":"30","author":"Clauw","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD008244.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1186\/ar4268","article-title":"Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial","volume":"15","author":"Clauw","year":"2013","journal-title":"Arthritis Research and Therapy"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2147\/JPR.S70200","article-title":"Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study","volume":"7","author":"Mease","year":"2014","journal-title":"Journal of Pain Research"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.080734","article-title":"The efficacy and safety or milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial","volume":"36","author":"Mease","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0012|cit12","first-page":"1975","article-title":"Efficacy of milnacipran in patients with fibromyalgia","volume":"32","author":"Gendreau","year":"2005","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/hup.622","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia","volume":"19","author":"Vitton","year":"2004","journal-title":"Human Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD008244.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/AJP.0b013e31827a784e","article-title":"Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial","volume":"29","author":"Ang","year":"2013","journal-title":"Clinical Journal of Pain"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2147\/IJGM.S36444","article-title":"Effect of milnacipran on body weight in patients with fibromyalgia","volume":"5","author":"Arnold","year":"2012","journal-title":"International Journal of General Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008244.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3899\/jrheum.101025","article-title":"Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study","volume":"38","author":"Branco","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","article-title":"Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study","volume":"11","author":"Goldenberg","year":"2010","journal-title":"Pain Medicine"},{"issue":"6 (Suppl 74)","key":"10.1002\/14651858.CD008244.pub3-BIB0018|cit18","first-page":"78","article-title":"Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis","volume":"30","author":"H\u00e4user","year":"2014","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008244.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"PCC.13m01555","DOI":"10.4088\/PCC.13m01555","article-title":"Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial","volume":"15","author":"Kim","year":"2013","journal-title":"Primary Care Companion for CNS Disorders"},{"issue":"5","key":"10.1002\/14651858.CD008244.pub3-BIB0020|cit20","first-page":"E553","article-title":"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Matthey","year":"2013","journal-title":"Pain Physician"},{"issue":"4","key":"10.1002\/14651858.CD008244.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/RHU.0000000000000103","article-title":"Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials","volume":"20","author":"Mease","year":"2014","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0022|cit22","unstructured":"A multicenter, randomized, open-label, controlled study to evaluate the safety, tolerability, and efficacy of milnacipran when added to pregabalin in the treatment of fibromyalgia, 2011 clinicaltrials.gov\/ct2\/show\/NCT00797797"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0023|cit23","unstructured":"Spera A Clauw DJ Arnold LM Ma Y Long-term efficacy and tolerability of milnacipran for the management of fibromyalgia: results from an open-label, flexible-dosing study followed by a randomized, double-blind, placebo-controlled discontinuation study Journal of General Internal Medicine. Conference: 35th Annual Meeting of the Society of General Internal Medicine, SGIM 2012"},{"issue":"12","key":"10.1002\/14651858.CD008244.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/AJP.0b013e31828440ab","article-title":"A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia","volume":"29","author":"Arnold","year":"2013","journal-title":"Clinical Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD008244.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1517\/14656566.2013.779670","article-title":"Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium","volume":"14","author":"Bernstein","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semarthrit.2011.06.003","article-title":"A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia","volume":"41","author":"Choy","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD008244.pub3-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011789","article-title":"Milnacipran for neuropathic pain in adults","author":"Derry","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0030|cit30","unstructured":"Higgins JPT Green S Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pain.2009.09.017","article-title":"How do changes in\u00a0pain\u00a0severity levels correspond to changes in health status and function in patients with painful\u00a0diabetic\u00a0peripheral\u00a0neuropathy?","volume":"149","author":"Hoffman\u00a0DL","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","article-title":"Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis","volume":"50","author":"H\u00e4user","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1002\/14651858.CD008244.pub3-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010292","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome","author":"H\u00e4user","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008244.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"f7339","DOI":"10.1136\/bmj.f7339","article-title":"Drugs for neuropathic pain","volume":"347","author":"Kalso","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD008244.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2377-11-55","article-title":"Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia","volume":"11","author":"Koroschetz","year":"2011","journal-title":"BMC Neurology"},{"issue":"9","key":"10.1002\/14651858.CD008244.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1345\/aph.1P218","article-title":"Milnacipran for treatment of fibromyalgia","volume":"44","author":"Kyle","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research","volume":"107","author":"L'Abb\u00e9","year":"1987","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008244.pub3-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0041|cit41","volume-title":"An Evidence-based Resource for Pain Relief","author":"McQuay","year":"1998"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0043|cit43","first-page":"15","article-title":"Managing potential publication bias","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain-establishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore\u00a0RA","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pain.2009.08.007","article-title":"Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD008244.pub3-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.pain.2010.11.030","article-title":"Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen\/paracetamol combinations after third molar extraction","volume":"152","author":"Moore","year":"2011","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD008244.pub3-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/EJA.0b013e328343c569","article-title":"Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion","volume":"28","author":"Moore","year":"2011","journal-title":"European Journal of Anaesthesiology"},{"issue":"12","key":"10.1002\/14651858.CD008244.pub3-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pain.2011.10.00","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD008244.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008244.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Moore","year":"2014","journal-title":"Pain Practice"},{"issue":"4","key":"10.1002\/14651858.CD008244.pub3-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub3","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008244.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions - individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JPR.S7883","article-title":"Milnacipran for the management of fibromyalgia syndrome","volume":"1","author":"Ormseth","year":"2010","journal-title":"Journal of Pain Research"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0060|cit60","unstructured":"PaPaS author and referee guidance papas.cochrane.org\/papas-documents"},{"issue":"8","key":"10.1002\/14651858.CD008244.pub3-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","article-title":"Worldwide epidemiology of fibromyalgia","volume":"17","author":"Queiroz","year":"2013","journal-title":"Current Pain and Headache Reports"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/JPR.S6792","article-title":"New and emerging therapeutic agents for the treatment of fibromyalgia: an update","volume":"22","author":"Recla","year":"2010","journal-title":"Journal of Pain Research"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0063|cit63","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"6","key":"10.1002\/14651858.CD008244.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1533-2500.2010.00441.x","article-title":"A meta-analysis of pain response in the treatment of fibromyalgia","volume":"11","author":"Roskell","year":"2011","journal-title":"Pain Practice"},{"issue":"4","key":"10.1002\/14651858.CD008244.pub3-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005454.pub2","article-title":"Antidepressants for neuropathic pain","author":"Saarto","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.nicl.2014.09.007","article-title":"Resting state connectivity correlates with drug and placebo response in fibromyalgia patients","volume":"6","author":"Schmidt-Wilcke","year":"2014","journal-title":"Neuroimage Clinical"},{"issue":"2","key":"10.1002\/14651858.CD008244.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2125.2008.03200.x","article-title":"Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review","volume":"66","author":"Straube","year":"2008","journal-title":"British Journal Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2474-11-150","article-title":"Pregabalin in fibromyalgia - responder analysis from individual patient data","volume":"11","author":"Straube","year":"2010","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1471-2474-12-125","article-title":"Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response","volume":"12","author":"Straube\u00a0S","year":"2011","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-29","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.tips.2004.10.002","article-title":"Bad news from the brain: descending 5-HT pathways that control spinal pain processing","volume":"2512","author":"Suzuki","year":"2004","journal-title":"Trends in the Pharmacological Sciences"},{"issue":"9859","key":"10.1002\/14651858.CD008244.pub3-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD008244.pub3-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010567.pub2","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","author":"Wiffen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008244.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD008244.pub3-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care and Research"},{"issue":"5","key":"10.1002\/14651858.CD008244.pub3-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/acr.21931","article-title":"Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population","volume":"645","author":"Wolfe","year":"2013","journal-title":"Arthritis Care and Research"},{"issue":"7","key":"10.1002\/14651858.CD008244.pub3-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/acr.22207","article-title":"What is fibromyalgia, how is it diagnosed and what does it really mean?","volume":"66","author":"Wolfe","year":"2014","journal-title":"Arthritis Care and Research"},{"issue":"3","key":"10.1002\/14651858.CD008244.pub3-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008244.pub2","article-title":"Milnacipran for neuropathic pain and fibromyalgia in adults","author":"Derry","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008244.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T08:04:00Z","timestamp":1669622640000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008244.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":78,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008244.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}